Dec 29, 2025 • MarketBeat
SOMEWHAT-BULLISH
Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from Brokerages
Immunovant, Inc. (NASDAQ:IMVT) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 1-year price target of $27.63. While insiders have recently sold shares, institutions and hedge funds have increased their positions in the clinical-stage biopharmaceutical company, which is developing the FcRn inhibitor efgartigimod. The company reported a quarterly EPS of -$0.73, slightly missing estimates, and has a market capitalization of $4.59 billion.
Dec 23, 2025 • MarketBeat
SOMEWHAT-BULLISH
Assenagon Asset Management S.A. Invests $3.31 Million in Immunovant, Inc. $IMVT
Assenagon Asset Management S.A. has invested $3.31 million in Immunovant, Inc. ($IMVT), acquiring 205,219 shares and establishing a new position in the company. Institutional investors now own 47.08% of Immunovant, while company insiders have been net sellers, offloading shares worth approximately $1.60 million in the last 90 days. The stock currently holds a "Moderate Buy" rating from analysts with an average price target of $27.63.
Dec 22, 2025 • Simply Wall Street
SOMEWHAT-BEARISH
How Investors Are Reacting To Immunovant (IMVT) $550 Million Follow-On Equity Raise And Dilution
Immunovant recently completed a significant $550.2 million equity offering, issuing 26,200,000 common shares at $21 each, substantially increasing its financial resources but also diluting existing shareholders. This capital raise aims to fund upcoming trials and launches, while the company's investment narrative now balances funding strength with dilution and governance concerns. The article highlights that despite the new capital, core clinical and dilution risks remain, with one valuation suggesting the shares might be trading at a premium.
Dec 20, 2025 • MarketBeat
NEUTRAL
Squarepoint Ops LLC Has $1.36 Million Stock Position in Immunovant, Inc. $IMVT
Squarepoint Ops LLC significantly increased its stake in Immunovant, Inc. (NASDAQ:IMVT) by 714.6% in the second quarter, bringing its total holdings to 84,919 shares valued at approximately $1.36 million. Immunovant is trading near its 12-month high with a market capitalization of $4.68 billion, and analysts generally rate it as a "Moderate Buy" with a consensus price target of $27.63. Despite institutional ownership of 47.08%, insiders have recently sold shares, reducing their ownership to 1.8%.
Dec 19, 2025 • MarketBeat
SOMEWHAT-BEARISH
Tuyl Christopher Van Sells 10,813 Shares of Immunovant (NASDAQ:IMVT) Stock
Tuyl Christopher Van, an insider at Immunovant (NASDAQ:IMVT), sold 10,813 shares of the company's stock on December 18th for approximately $290,978, reducing his stake by 6.73%. The biotech company's stock closed at $26.68 on Friday with high trading volume and a market capitalization of $4.68 billion. Immunovant recently missed analyst EPS estimates and currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $27.63.
Dec 19, 2025 • Yahoo Finance
NEUTRAL
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?
Roivant Sciences Ltd. recently increased its stake in Immunovant (NASDAQ:IMVT) by acquiring 16,666,666 shares for approximately $350 million. This significant purchase, made at a discount to the market price, increases Roivant's direct ownership to over 64% of Immunovant's outstanding shares. The investment aims to fund Immunovant's medical research and clinical trials for its lead drug candidate, IMVT-1402, making Immunovant a high-risk, high-reward prospect dependent on favorable trial results and FDA approval.